[Federal Register Volume 87, Number 10 (Friday, January 14, 2022)]
[Notices]
[Page 2440]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-00704]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Award of a Single-Source Cooperative Agreement To Fund 
the All-India Institute for Medical Sciences, New Delhi (AIIMS, New 
Delhi)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), located 
within the Department of Health and Human Services (HHS), announces the 
award of approximately $2,000,000, with an expected total funding of 
approximately $10,000,000 over a five-year period, to AIIMS, New Delhi. 
The award will support research to estimate the incidence of influenza 
and other respiratory viruses (such as SARS-CoV-2) among working-age 
adults and other priority populations in India to strengthen the 
evidence base and inform influenza vaccine policy in India.

DATES: The period for this award will be September 30, 2022, through 
September 29, 2027.

FOR FURTHER INFORMATION CONTACT: Amy Yang, Ph.D., National Center for 
HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease 
Control and Prevention, 1600 Clifton Road NE, MS US8-1, Atlanta, GA 
30329, Telephone: 404-718-8835, email: <a href="/cdn-cgi/l/email-protection#beddd1cccee1dbccced1e186868d8bfedddadd90d9d1c8"><span class="__cf_email__" data-cfemail="65060a17153a0017150a3a5d5d5650250601064b020a13">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: This single-source award will allow the 
recipient to conduct research to estimate the incidence of influenza 
and other respiratory viruses (such as SARS-CoV-2) among working-age 
adults and other priority populations in India to strengthen the 
evidence base and inform influenza vaccine policy in India.
    AIIMS, New Delhi, is in a unique position to conduct this work, as 
it is the only institution in India with the required scientific and 
technical expertise to conduct multi-site cohort studies on influenza 
and other respiratory viruses like SARS-CoV-2 which require robust 
epidemiological and laboratory capacity and maintains the high research 
standards required by CDC. AIIMS, New Delhi, is governmentally mandated 
by the AIIMS Act of 1956 and operates autonomously as an institution of 
national importance under the Ministry of Health and Family Welfare. 
AIIMS, New Delhi, is the leader of basic, clinical, and translational 
medical research in India.

Summary of the Award

    Recipient: The All-India Institute for Medical Sciences, New Delhi 
(AIIMS, New Delhi).
    Purpose of the Award: The purpose of this award is to support 
research to estimate the incidence of influenza and other respiratory 
viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), among working-aged adults and other priority populations in 
India to strengthen the evidence base to help inform influenza vaccine 
policy in India. The recipient will set up a multi-center hospital-
based platform in India to estimate the disease and economic burden of 
influenza- and COVID-19-associated hospitalization of working age 
adults (18-60 years) in India. An additional goal is to increase 
awareness about influenza burden and prevention methods among 
clinicians and public health practitioners. This project aligns with 
activities conducted under the CDC Influenza Division's International 
Program to build the evidence base for better understanding the disease 
and economic burden of influenza and to identify strategies for 
influenza prevention, including vaccination in low- and middle-income 
settings.
    Amount of Award: $2,000,000 in Federal Fiscal Year (FYY) 2022 
funds, and an estimated $2,000,000 for each subsequent 12-month budget 
period over five years, subject to availability of funds.
    Authority: This program is authorized under Public Health Service 
Act, Section 307 (42 U.S.C. 242l).
    Period of Performance: September 30, 2022 through September 29, 
2027.

    Dated: January 11, 2022.
Terrance Perry,
Chief Grants Management Officer, Centers for Disease Control and 
Prevention.
[FR Doc. 2022-00704 Filed 1-13-22; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>